Stockcoach1 wrote: Not sure about Apple, but the comparison isn't possible as Concordia will never be an Apple, even though their share price may be similarly priced . Apple is a mature household name company that split it's stock with 5.7 Billion shares outstanding, while Concordia in comparison is a tiny newcomer in a niche pharma market with only 33 million shares.
Exceptional quality startups can easily outperform mature names. In fact if CEO Thompson was to start a new pharma company based on the CXR model, I would redirect my funds from CXR. The chances to 10 times my money in the new venture at initial stages are much greater than CXR going up 10 times from these levels.
Here are the reasons CXR is where it is;
- Top notch experienced management
- Flawlessly Executed every transaction to build confidence
- Tight hold on outstanding shares ....little dilution
- Essentially a 3% tax structure
- Future growth by acquisition
- Growing and expanding health need for decades to come.
Thanks Nick. Now if only it was easy to find startups that duplicate that!